Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody + HIPEC + CapeOX for newly diagnosed gastric cancer with peritoneal metastasis
ChiCTR2300067467Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody, capecitabine and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Guangdong Provincial People's Hospital. Primary endpoint: R0 resection rate. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibodycapecitabineoxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300067467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067467.